Long-Acting Injectable Prep for People Who Inject Drugs at a Syringe Services Program: A Qualitative Acceptability and Feasibility Study
- PMID: 39779623
- PMCID: PMC11985550
- DOI: 10.1007/s10461-024-04598-3
Long-Acting Injectable Prep for People Who Inject Drugs at a Syringe Services Program: A Qualitative Acceptability and Feasibility Study
Abstract
Although people who inject drugs (PWID) are at high risk of acquiring HIV, knowledge and uptake of pre-exposure prophylaxis (PrEP) for HIV prevention among this population remain low due to numerous psychosocial and structural barriers. Multiple implementation strategies have been proposed to address this gap, notably providing long-acting injectable (LAI) formulations of PrEP and offering PrEP at syringe services programs (SSPs). This qualitative study explores the acceptability and feasibility of offering LAI-PrEP for PWID at risk for HIV at Florida's first legal SSP. In-depth semi-structured interviews were conducted with PWID (n = 25) and healthcare providers (n = 5), and transcripts were analyzed using iterative thematic analysis. The provision of LAI-PrEP at the SSP was overwhelmingly acceptable to both PWID and providers, and specific advantages and disadvantages of LAI-PrEP compared to oral PrEP among this population were elucidated. Likewise, PWID and providers identified facilitators and barriers to offering LAI-PrEP at the SSP and proposed recommendations for implementation. Overall, this study adds to the growing evidence that provision of LAI-PrEP at SSPs is acceptable and feasible and holds promise in expanding access to and uptake of HIV prevention services among PWID.
Keywords: HIV; People who Inject Drugs; PrEP; Syringe Services Programs.
© 2024. The Author(s).
Conflict of interest statement
Declarations. Ethics Approval and Consent to Participate: The study was approved by the University of Miami Institutional Review Board in March of 2022 (IRB# 20220127). Informed consent was obtained from all participants included in this study. Consent for Publication: Not applicable. Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: TSB and HET receive research funding from Gilead Sciences.
Similar articles
-
Preferences for on-demand/intermittent/event-driven and long-acting injectable (LAI) HIV pre-exposure prophylaxis (PrEP) among HIV-negative Black gay, bisexual, and other sexual minority men in the United States: A qualitative study.PLoS One. 2025 Jun 30;20(6):e0323212. doi: 10.1371/journal.pone.0323212. eCollection 2025. PLoS One. 2025. PMID: 40587467 Free PMC article.
-
COVID-19 vaccine implementation at a syringe services program: experiences of frontline staff.BMC Health Serv Res. 2024 Oct 19;24(1):1260. doi: 10.1186/s12913-024-11691-9. BMC Health Serv Res. 2024. PMID: 39427164 Free PMC article.
-
Rapid initiation of antiretrovirals at a syringe services program for people with HIV who inject drugs.Ann Med. 2025 Dec;57(1):2461670. doi: 10.1080/07853890.2025.2461670. Epub 2025 Feb 10. Ann Med. 2025. PMID: 39928115 Free PMC article.
-
Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.Cochrane Database Syst Rev. 2017 Sep 18;9(9):CD012021. doi: 10.1002/14651858.CD012021.pub2. Cochrane Database Syst Rev. 2017. PMID: 28922449 Free PMC article.
-
Pre-exposure prophylaxis (PrEP) among people who use drugs: a qualitative scoping review of implementation determinants and change methods.Addict Sci Clin Pract. 2024 May 30;19(1):46. doi: 10.1186/s13722-024-00478-2. Addict Sci Clin Pract. 2024. PMID: 38816889 Free PMC article.
Cited by
-
Willingness to Take Long-Acting Injectable Preexposure Prophylaxis (PrEP) and Preference for PrEP Modalities Among People Who Inject Drugs in Washington, DC.Open Forum Infect Dis. 2025 Jul 3;12(7):ofaf389. doi: 10.1093/ofid/ofaf389. eCollection 2025 Jul. Open Forum Infect Dis. 2025. PMID: 40672761 Free PMC article.
-
"The Simplest Way to Go": An Exploration of Why Women Who Inject Drugs Chose Long-Acting Injectable Cabotegravir Instead of Daily Oral PrEP.AIDS Behav. 2025 Aug 6. doi: 10.1007/s10461-025-04833-5. Online ahead of print. AIDS Behav. 2025. PMID: 40767995
References
-
- Assefa Y, Gilks CF. Ending the epidemic of HIV/AIDS by 2030: will there be an endgame to HIV, or an endemic HIV requiring an integrated health systems response in many countries? Int J Infect Dis. 2020;100:273–7. - PubMed
-
- Kim N, et al. Undiagnosed and untreated HIV infection among persons who inject drugs: results of three National HIV behavioral surveillance surveys, San Francisco, 2009–2015. AIDS Behav. 2019;23(6):1586–9. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous